EGFR mutations, prevalent in approximately 15% of western and 40% of Asian NSCLC patient populations, are significant targets in oncology, with EGFR tyrosine kinase inhibitors (TKIs) dramatically altering the treatment landscape [92]. Here, EGFR is linked to non-small cell lung carcinoma.